Skip to main content

Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.

Publication ,  Journal Article
Birnbaum, A; Dipetrillo, T; Rathore, R; Anderson, E; Wanebo, H; Puthwala, Y; Joyce, D; Safran, H; Henderson, D; Kennedy, T; Ready, N; Sio, TT-W
Published in: Am J Clin Oncol
April 2010

OBJECTIVE: To determine the feasibility and toxicity of the addition of cetuximab to paclitaxel, carboplatin, and concurrent radiation for patients with head and neck cancer. MATERIALS AND METHODS: Patients with stage III or IV locally advanced squamous cell cancer of the head and neck, without distant organ metastases, were eligible. Patients received 4 weeks of induction cetuximab followed by weekly cetuximab, paclitaxel, carboplatin, and concurrent radiation. RESULTS: Thirty-two patients were assessable for chemoradiation toxicities. Grade 3 and grade 4 mucositis occurred in 53% and 16% of patients, respectively. Grade 3 and grade 4 radiation dermatitis occurred in 44% and 9% of patients, respectively. Grade 3/4 radiation dermatitis was associated with the use of intensity modulated radiation therapy (64% vs.14%, respectively, P < 0.0001). Grade 3 and grade 4 cetuximab associated acneiform rash developed in 6% and 3% of patients. Overall 21 patients (66%) had any grade 3 toxicity and 10 patients (31%) had any grade 4 toxicity. The percentages of the intended total dose delivered of carboplatin, cetuximab, paclitaxel, and radiation were 86%, 89%, 89%, and 96%, respectively. CONCLUSION: Cetuximab, when combined with paclitaxel, carboplatin and intensity modulated radiation therapy, increases dermatologic toxicity but does not increase mucosal toxicity as compared with previous Brown University Oncology Group studies of paclitaxel, carboplatin, and conventional radiation for patients with head and neck cancer.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Clin Oncol

DOI

EISSN

1537-453X

Publication Date

April 2010

Volume

33

Issue

2

Start / End Page

144 / 147

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Survival Rate
  • Radiotherapy Dosage
  • Radiodermatitis
  • Prospective Studies
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Mucositis
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Birnbaum, A., Dipetrillo, T., Rathore, R., Anderson, E., Wanebo, H., Puthwala, Y., … Sio, T.-W. (2010). Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis. Am J Clin Oncol, 33(2), 144–147. https://doi.org/10.1097/COC.0b013e3181979093
Birnbaum, Ariel, Thomas Dipetrillo, Ritesh Rathore, Elliott Anderson, Harry Wanebo, Yacoub Puthwala, Donald Joyce, et al. “Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.Am J Clin Oncol 33, no. 2 (April 2010): 144–47. https://doi.org/10.1097/COC.0b013e3181979093.
Birnbaum A, Dipetrillo T, Rathore R, Anderson E, Wanebo H, Puthwala Y, et al. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis. Am J Clin Oncol. 2010 Apr;33(2):144–7.
Birnbaum, Ariel, et al. “Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.Am J Clin Oncol, vol. 33, no. 2, Apr. 2010, pp. 144–47. Pubmed, doi:10.1097/COC.0b013e3181979093.
Birnbaum A, Dipetrillo T, Rathore R, Anderson E, Wanebo H, Puthwala Y, Joyce D, Safran H, Henderson D, Kennedy T, Ready N, Sio TT-W. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis. Am J Clin Oncol. 2010 Apr;33(2):144–147.

Published In

Am J Clin Oncol

DOI

EISSN

1537-453X

Publication Date

April 2010

Volume

33

Issue

2

Start / End Page

144 / 147

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Survival Rate
  • Radiotherapy Dosage
  • Radiodermatitis
  • Prospective Studies
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Mucositis
  • Middle Aged